TScan Therapeutics (NASDAQ:TCRX) Posts Earnings Results, Misses Expectations By $0.06 EPS

TScan Therapeutics (NASDAQ:TCRX) announced its earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06), FiscalAI reports. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%. The firm had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.46 million.

TScan Therapeutics Trading Down 9.5%

TCRX opened at $0.17 on Friday. TScan Therapeutics has a 1-year low of $0.16 and a 1-year high of $1.47. The stock has a market capitalization of $11.39 million, a PE ratio of -0.18 and a beta of 1.21. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average price of $0.26 and a two-hundred day moving average price of $0.81.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TCRX. Benchmark reaffirmed a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Lifesci Capital lowered shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. HC Wainwright cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a research note on Tuesday, September 8th. Weiss Ratings downgraded TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Finally, Wedbush downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a report on Wednesday, September 2nd. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.67.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells. The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.